Incyte partners with Caris Life Sciences to advance oncology pipeline
Moyo Studio/E+ via Getty Images
- Caris Life Sciences (Caris) announces a strategic research partnership with Incyte (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline.
- The partnership will apply Caris' data and analytics tools, comprehensive molecular tissue and liquid profiling services, and clinical trial enrollment program capabilities across two therapeutic programs initially, with the option for Incyte to expand to four total programs.
- Under the terms of the agreement, Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs.
- For drug candidates developed under the collaboration, patients enrolled in Incyte-led clinical trials will undergo longitudinal testing with Caris' comprehensive tissue and liquid molecular profiling assays.
- Incyte will also leverage Caris' biomarker-driven patient selection for clinical trials including options to partner on developing companion diagnostics for programs in the partnership.